君实生物(688180.SH)：抗IL-17A单抗治疗中重度斑块状银屑病的Ⅲ期临床研究达到主要研究终点

Core Viewpoint - Junshi Biosciences (688180.SH) announced positive results from a pivotal Phase III clinical trial for its product JS005, a humanized anti-IL-17A monoclonal antibody, in treating moderate to severe plaque psoriasis [1] Group 1 - The clinical study (JS005-005-III-PsO) was a multicenter, randomized, double-blind, parallel, placebo-controlled trial [1] - Both primary and key secondary endpoints showed statistically significant and clinically meaningful improvements [1] - The company plans to submit a marketing authorization application to regulatory authorities in the near future [1]